Cargando…
Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice
No treatment is available to address the neurological need and reversibility of MPS II. We developed a scAAV9-hIDS vector to deliver the human iduronate-2-sulfatase gene and test it in mouse model. We treated MPS II mice at different disease stages with an intravenous injection of scAAV9-mCMV-hIDS a...
Autores principales: | Fu, Haiyan, Zaraspe, Kim, Murakami, Naoko, Meadows, Aaron S., Pineda, Ricardo J., McCarty, Douglas M., Muenzer, Joseph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125796/ https://www.ncbi.nlm.nih.gov/pubmed/30191159 http://dx.doi.org/10.1016/j.omtm.2018.07.005 |
Ejemplares similares
-
Functional correction of neurological and somatic disorders at later stages of disease in MPS IIIA mice by systemic scAAV9-hSGSH gene delivery
por: Fu, Haiyan, et al.
Publicado: (2016) -
Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector
por: Bobo, Tierra A., et al.
Publicado: (2020) -
Systemic scAAV9 variant mediates brain transduction in newborn rhesus macaques
por: Dehay, Benjamin, et al.
Publicado: (2012) -
Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice
por: McCarty, D M, et al.
Publicado: (2009) -
Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa
por: MacLachlan, Timothy K., et al.
Publicado: (2017)